Logo image of DRUG

BRIGHT MINDS BIOSCIENCES INC (DRUG) Stock Fundamental Analysis

NASDAQ:DRUG - Nasdaq - CA10919W4056 - Common Stock - Currency: USD

28  +0.91 (+3.36%)

After market: 26.8 -1.2 (-4.29%)

Fundamental Rating

2

Overall DRUG gets a fundamental rating of 2 out of 10. We evaluated DRUG against 558 industry peers in the Biotechnology industry. While DRUG seems to be doing ok healthwise, there are quite some concerns on its profitability. DRUG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

DRUG had negative earnings in the past year.
DRUG had a negative operating cash flow in the past year.
In the past 5 years DRUG always reported negative net income.
DRUG had a negative operating cash flow in each of the past 5 years.
DRUG Yearly Net Income VS EBIT VS OCF VS FCFDRUG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

DRUG has a Return On Assets of -6.10%. This is amongst the best in the industry. DRUG outperforms 87.10% of its industry peers.
DRUG's Return On Equity of -6.18% is amongst the best of the industry. DRUG outperforms 89.43% of its industry peers.
Industry RankSector Rank
ROA -6.1%
ROE -6.18%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRUG Yearly ROA, ROE, ROICDRUG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

DRUG does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRUG Yearly Profit, Operating, Gross MarginsDRUG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for DRUG has been increased compared to 5 years ago.
DRUG Yearly Shares OutstandingDRUG Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2024 1M 2M 3M 4M
DRUG Yearly Total Debt VS Total AssetsDRUG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2024 5M 10M 15M 20M

2.2 Solvency

DRUG has an Altman-Z score of 217.10. This indicates that DRUG is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of DRUG (217.10) is better than 99.64% of its industry peers.
DRUG has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
DRUG has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: DRUG outperforms 46.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 217.1
ROIC/WACCN/A
WACCN/A
DRUG Yearly LT Debt VS Equity VS FCFDRUG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

A Current Ratio of 88.27 indicates that DRUG has no problem at all paying its short term obligations.
DRUG has a better Current ratio (88.27) than 100.00% of its industry peers.
DRUG has a Quick Ratio of 88.27. This indicates that DRUG is financially healthy and has no problem in meeting its short term obligations.
DRUG has a better Quick ratio (88.27) than 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 88.27
Quick Ratio 88.27
DRUG Yearly Current Assets VS Current LiabilitesDRUG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2024 5M 10M 15M 20M

More info and screens

0

3. Growth

3.1 Past

DRUG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.66%, which is quite impressive.
EPS 1Y (TTM)60.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-225.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DRUG. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRUG Price Earnings VS Forward Price EarningsDRUG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRUG Per share dataDRUG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DRUG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIGHT MINDS BIOSCIENCES INC

NASDAQ:DRUG (6/24/2025, 4:29:08 PM)

After market: 26.8 -1.2 (-4.29%)

28

+0.91 (+3.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners67.81%
Inst Owner Change6.55%
Ins Owners22.76%
Ins Owner ChangeN/A
Market Cap197.12M
Analysts85.71
Price TargetN/A
Short Float %1.59%
Short Ratio3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.88
P/tB 4.88
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS5.74
TBVpS5.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.1%
ROE -6.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 88.27
Quick Ratio 88.27
Altman-Z 217.1
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-225.97%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.81%
OCF growth 3YN/A
OCF growth 5YN/A